Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A thymic peptide that plays a central role in immune system regulation. Approved as a drug in over 35 countries (though not in the US) for hepatitis B and C treatment and as an immune booster.
A synthetic fragment of thymosin beta-4, a naturally occurring peptide involved in tissue repair and regeneration. Widely used in the biohacking community for injury recovery.
Enhances T-cell function, promotes dendritic cell maturation, and modulates cytokine production. Acts as an immune system regulator rather than a simple stimulant, helping to balance immune responses.
Promotes cell migration, blood vessel formation, and reduces inflammation. Upregulates actin, a cell-building protein critical for healing and cell migration to injury sites.
- Immune system support
- Chronic infection management
- Cancer adjunct therapy (in some countries)
- Post-illness recovery
- Autoimmune condition management
- Muscle and tendon repair
- Wound healing
- Reducing inflammation
- Hair regrowth (emerging research)
- Cardiac tissue repair
- Generally well-tolerated in clinical use
- Injection site reactions
- Rare allergic reactions
- May interact with immunosuppressive drugs
- Limited human clinical data
- Potential tumor growth concerns (theoretical)
- Injection site reactions
- Headaches reported anecdotally
Reclassified to Category 1 in February 2026 as part of the HHS announcement restoring compounding access. Not affected by the April 15, 2026 Category 2 removal action. Approved as Zadaxin in 35+ countries but not FDA-approved in the US. Available through licensed 503A compounding pharmacies with a physician prescription.
On April 15, 2026, the FDA announced TB-500 will be removed from the Category 2 'significant safety risks' list effective April 22, 2026. Scheduled for PCAC review on July 23, 2026 to determine eligibility for the 503A bulk drug substances list. Compounding pharmacies should exercise caution until PCAC takes action.
PCAC: July 23, 2026
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.